ArticleThe oncologist2025

Novel anti-HER2 ADCs vs dual anti-HER2 antibody for HER2-positive metastatic breast cancer failed to tyrosine kinase inhibitor.

Feng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.